Please assess the completion status of the following clinical trial:

Trial Title: Immunogenicity, Safety of Measles-mumps-rubella-varicella Vaccine (MeMuRu-OKA) Compared to Priorix™ Given With Varilrix™

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Children must be healthy to participate~Exclusion Criteria:~* Immunosuppressive (including HIV) conditions, allergic diseases, neurological disorders, known anaphylactic reaction to MMR vaccine, and fever (axillary temperature ³ 37.5°C at the time of vaccination) are excluding factors.~* Children must have received one dose (but not more) of MMR at least 6 weeks before entering the study.~* They must not receive or have received other non-registered drug or vaccine within 30 days prior to study start, or immunosuppressants for more than 14 days.~* Immunoglobulins or any blood products are prohibited during the 6 months before and during the study, as well as vaccine other than that foreseen by the protocol, 30 days before until 56 days after vaccination.~* Children must not have been vaccinated against varicella.~* They must not have had measles, mumps, rubella or varicella, or have been exposed to those diseases within 30 days prior to study start.~* New-born infants (\< 5 weeks of age), pregnant women without previous exposure to chickenpox, and immunodeficient persons cannot live in the same household as the vaccinated child.

- Gender: ALL
- Minimum Age: 15 Months
- Maximum Age: 6 Years
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).